<DOC>
	<DOCNO>NCT02267993</DOCNO>
	<brief_summary>In single-center , randomize , open-label , crossover , prospective clinical trial , total 120 AML patient achieve remission randomize two group , 60 case group . Each subject require undergo two cycle chemotherapy . At treatment cycle , patient receive subcutaneous injection rhTPO . At control cycle , rhTPO therapy given.The safety rhTPO evaluate monitoring liver renal function , blood coagulation , TPO-neutralizing antibody , adverse event associate rhTPO treatment record study period .</brief_summary>
	<brief_title>Efficacy Safety rhTPO Treatment Thrombocytopenia After Chemotherapy AML Patients</brief_title>
	<detailed_description>In single-center , randomize , open-label , crossover , prospective clinical trial , total 120 AML patient achieve remission follow induction chemotherapy recruit randomize two group , 60 case group . For one group , treatment cycle first chemotherapy cycle control cycle second one . For another group , treatment cycle second chemotherapy cycle control cycle first one . Each subject require undergo two cycle chemotherapy . At treatment cycle , patient receive subcutaneous injection rhTPO dose 300 U/kg body weight daily platelet count &lt; 50×109/L , rhTPO treatment cease platelet count ≥20×109/L platelet transfuse . At control cycle , rhTPO therapy give . Each subject require follow successive two chemotherapy cycle follow inclusion study . During follow-up period , routine blood test perform every day , platelet transfusion record . The safety rhTPO evaluate monitoring liver renal function , blood coagulation , TPO-neutralizing antibody , adverse event associate rhTPO treatment record study period .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>1 . Age 1855 year ; 2 . Patients meet diagnostic criterion acute myeloid leukemia ( except M3 M7 subtypes ) , achieve complete remission follow induction chemotherapy undergo consolidation therapy ; 3 . Patients require two successive cycle DA ( Arac 1.5 g/m2/q12 h DNR 40 mg/m2/d day 13 ) MA regimen ( AraC 1.5 g/m2/q12 h MTZ 6 mg/m2/d day 13 ) phase consolidation therapy , underwent consolidation therapy administration AraC 3 g/m2/q12 h alone , dose adjustment le 10 % AraC dose ; 4 . Patients minimum platelet count &lt; 30´109/L final cycle chemotherapy induction stage ; 5 . Patients without apparent liver renal dysfunction ( serum level urea nitrogen , creatinine , aminotransferase bilirubin ≤ 1.5 time normal upper limit ) ; 6 . Patients without severe heart lung dysfunction ; 7 . Patients life expectancy &gt; 12 week ; 8 . Patients ECOG score ≤ 2 ; 9 . Patients willing participate study sign inform consent . 1 . Patients medical history severe allergy biologics ; 2 . Patients thromboembolic hemorrhagic disease , recent medical history thrombosis ; 3 . Patients history mental disorder ; 4 . Pregnant lactating patient , patient failure use contraception study period ; 5 . Patients M3 M7 subtype ; 6 . Patients platelet count 1000 ´109/L start study ; 7 . Patients factor consider suitable participate study investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>